RACP

Over the last decade, immune checkpoint inhibitors (ICIs) have changed the landscape of cancer treatment. However, they are associated with immune related adverse reactions (irARs) which can impact a wide variety of body organs or systems. This activity is designed to increase confidence in initiating steroids to manage irARs in patients receiving immuno-oncology (IO) treatments and showcase the nuances of steroid usage for irARs.

Learning outcomes


By the end of this activity, participants will be able to:

  • Outline the appropriate use of steroids as initial treatment (plus the consideration of biologics and other immunosuppressants) for irARs
  • Outline the appropriate dose of steroids for patients who experience irARs, including the initial dose and the dosing regimen for tapering off steroids
  • Identify the roles of the patient and other members of the hospital team in the management of irARs
  • Describe the value of creating networks with other oncologists and organ specialists to achieve the most successful management of irARs.
RACP

This activity has been designed to take 1 hour to complete and is suitable for 1 hour of Category 1 Educational Activity learning in the RACP myCPD Programme.

Other healthcare professionals can still enrol and complete this course.
You will receive a certificate upon completion.

START LEARNING

If you do not already have an account with Arterial Education, you will be required to create one. This verifies that you are a healthcare professional and allows you to log your learning activities.